New drug cocktail aims to cut bleeding and heart attacks in atrial fibrillation patients

NCT ID NCT03331484

Completed Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, rivaroxaban and ticagrelor, in 40 patients with atrial fibrillation who had a stent placed. The goal was to see if this combo causes less bleeding and prevents heart attacks or strokes better than current treatments. Patients took the drugs for one year, and researchers tracked bleeding events and heart-related outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rivaroxaban and Ticagrelor
What this could lead to: If successful, this could point toward a safer, more effective drug combination for managing heart disease in patients with atrial fibrillation after stent placement.
What could go wrong: This is a small, non-randomized study with only 40 participants, so results may not apply broadly. Bleeding risks remain a concern with these potent drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome atrial fibrillation Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME ATRIAL FIBRILLATION

Contacts and locations

Locations

University of Ottawa Heart Institute

Ottawa, Ontario, K1Y 4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.